Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection
Fig 1
Frequency of lymphopenias in various treatment groups.
Shown are the frequencies of lymphopenias patients treated receiving vemurafenib (VEM) or dabrafenib (DAB), with or without concomitant corticosteroid therapy (dexamethasone—DEX). * = p < 0.05 marking statistically significant differences between groups; n = number of patients